Chemomab Therapeutics Ltd. (CMMB) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001534248 · SEC filings checked Oct 17, 2026
Next report
Dec 2, 2026
Estimated from reporting history (95-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
Last close
$1.26
Polygon.io daily close, Oct 16, 2026. End of day, not live.
Trailing diluted EPS
—
Needs four consecutive reported quarters.
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2025 | Aug 14, 2025 | Announced; figures arrive with the 10-Q | $-2.1M | — | Filing |
| Mar 31, 2025 | — | Announced; figures arrive with the 10-Q | $-3.3M | — | — |
| Jun 30, 2024 | Aug 21, 2024 | — | $-3.6M | $0.01 | Filing |
| Mar 31, 2024 | — | Announced; figures arrive with the 10-Q | $-3.9M | — | — |
| Jun 30, 2023 | Aug 14, 2023 | — | $-8.0M | $0.04 | Filing |
| Mar 31, 2023 | May 11, 2023 | — | $-8.8M | $0.04 | Filing |
| Dec 31, 2022 | Feb 21, 2023 | — | $-8.3M | $0.04 | Filing |
| Sep 30, 2022 | Nov 10, 2022 | — | $-8.1M | $0.04 | Filing |
What would Chemomab Therapeutics Ltd. have to report for its valuation to change?
Four consecutive reported quarters of diluted EPS are not available in SEC filings. The model is not shown rather than filled with assumptions.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.